Amgen Inc. (AMGN)’s Nplate Effective for GI Cancer Thrombocytopaenia

Amgen Inc. (NASDAQ:AMGN)’s thrombocytopenia drug Nplate (romiplostim) showed significant benefits in a Phase III trial for gastrointestinal (GI) cancer patients, as presented at the 2025 ASCO Annual Meeting.

The RECITE trial involved 165 patients with colorectal, gastroesophageal, or pancreatic cancer receiving oxaliplatin-based chemotherapy. Patients were randomized 2:1 to receive Nplate or placebo over three chemotherapy cycles.

Amgen Inc. (AMGN)’s Nplate Effective for GI Cancer Thrombocytopaenia

A pharmacist filling a prescription for a complex drug developed by the company.

Results demonstrated that 84% of patients treated with Nplate avoided dose modifications of immunosuppressive chemotherapy, compared to only 36% on placebo. Nplate also accelerated platelet recovery, with 97% of patients responding versus 77% on placebo, and a median time to response of 1.1 weeks compared to 2.1 weeks. Platelet counts increased significantly (87×10⁹/L vs. 58×10⁹/L), reducing bleeding risks.

The safety profile was favorable, with mild treatment-related adverse events reported by 12% of Nplate patients and 7% of placebo patients. No serious adverse events or discontinuations occurred.

Originally approved in 2008 for immune thrombocytopenic purpura, Nplate’s new indication in chemotherapy-induced thrombocytopenia could be practice-changing. Despite looming patent expiry in 2028, this data may strengthen Nplate’s role in oncology, potentially improving outcomes for cancer patients worldwide.

Amgen Inc. (NASDAQ:AMGN), based in Thousand Oaks, California, is a global biopharmaceutical company specializing in the discovery, development, and manufacture of human therapeutics. Its diverse portfolio targets key areas such as oncology and inflammatory diseases. Committed to innovation and responsible practices, Amgen aims to improve patient outcomes worldwide.

While we acknowledge the potential of AMGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.